The FDA recently released a draft guidance document entitled “Assessing User Fees Under the Biosimilar User Fee Amendments of 2017.” The guidance is meant to address various industry inquiries around the implementation of the Biosimilar User Fee Amendments II (BsUFA II).
The FDA recently released a draft guidance document entitled “Assessing User Fees Under the Biosimilar User Fee Amendments of 2017.” The guidance is meant to address various industry inquiries around the implementation of the Biosimilar User Fee Amendments II (BsUFA II). Specifically, the document addresses the changes to the user fee program and provides an explanation about the new fee structure and types of fees that entities are responsible to pay.
The Biosimilar User Fee Act of 2012 (BsUFA I) authorized the FDA to collect user fees for a 5-year period from biosimilar developers. Such fees help to fund the review process of biosimilar product applications and have played an important role in expediting the process. BsUFA II extended the FDA’s authority to collect user fees from fiscal year 2018 through fiscal year 2022 and revised the required fees and how they are collected.
The BsUFA II sanctioned the collection of 3 types of fees:
These fees differ from the BsUFA I because they eliminated fees required for supplements as well as biosimilar biological product establishment fees. In addition, the BsUFA II also removed the reduction of an application fee by the cumulative amount of fees paid by the applicant under the BDP.
The guidance provides an overview of when these fees are incurred and the process by which applicants must submit payments. Should a developer fail to pay the required fees, the document also addresses the consequences and the means for submitting reconsideration and appeal requests.
According to the FDA, if an applicant has failed to pay any BDP fee (initial, annual, or reactivation) for a product, the FDA will not host a BDP meeting relating to the product for which fees are owed, consider an investigational new drug submitted for the product if the FDA determines the investigation is intended to support a biosimilar biological product application, or allow the sponsor of a clinical investigation from continuing the investigation if the FDA determines it is to support a biosimilar biological product application.
The FDA has noted that this guidance does not include any substantive changes from the previous draft guidance. Industry members and other stakeholders are able to submit comments on the guidance to the Federal Register.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.